Board meeting on 5 November to approve September 2026 results

Revenue growth above 20%Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹263.85

prior close

₹263.50

announcement price

After-mkt

timing

Nifty Microcap 250market-2.5%+0.8% vs market

Healthcare Research Analytics & Technology peers, median of 5sector-3.7%+2.0% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 2.0 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-1.0

15m

-0.4

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6-2.5+0.8-3.7+2.0

Next day

+3.5-1.1+4.6+1.1+2.4

-0.8-0.8+0.1+1.0-1.8

+4.0+1.3+2.7+3.3+0.8

+4.7pendingpending+3.7+1.1

+1.0pendingpending+2.9-2.0

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences will hold a board meeting on 5 November 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window has been closed since 1 October and remains closed until 48 hours after the results are declared.

Likely market impact

Only the approval date is disclosed. No earnings figures or financial details are provided, so the stock impact cannot yet be assessed.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹1.20 Cr	₹0.92 Cr	+30.4%
Profit after tax	−₹106.9 Cr	−₹77.31 Cr	loss widened

From the company's XBRL filing, not from the text above. Operating profit and EBITDA margin are not shown for banks and lenders, whose other income is their business.